MX2017016101A - Polinucleotidos y polipetidos de adenovirus. - Google Patents

Polinucleotidos y polipetidos de adenovirus.

Info

Publication number
MX2017016101A
MX2017016101A MX2017016101A MX2017016101A MX2017016101A MX 2017016101 A MX2017016101 A MX 2017016101A MX 2017016101 A MX2017016101 A MX 2017016101A MX 2017016101 A MX2017016101 A MX 2017016101A MX 2017016101 A MX2017016101 A MX 2017016101A
Authority
MX
Mexico
Prior art keywords
amino acid
acid sequence
seq
polypeptide
polypeptides
Prior art date
Application number
MX2017016101A
Other languages
English (en)
Spanish (es)
Inventor
Nicosia Alfredo
Vitelli Alessandra
Colloca Stefano
Grazioli Fabiana
Ammendola Virginia
Cortese Riccardo
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2015/063248 external-priority patent/WO2015189425A1/en
Priority claimed from GBGB1510357.5A external-priority patent/GB201510357D0/en
Priority claimed from GBGB1514772.1A external-priority patent/GB201514772D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of MX2017016101A publication Critical patent/MX2017016101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2017016101A 2015-06-12 2016-06-10 Polinucleotidos y polipetidos de adenovirus. MX2017016101A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2015/063248 WO2015189425A1 (en) 2014-06-13 2015-06-12 Immunogenic combinations
GBGB1510357.5A GB201510357D0 (en) 2015-06-12 2015-06-12 Adenovirus polynucleotides and polypeptides
GBGB1514772.1A GB201514772D0 (en) 2015-08-19 2015-08-19 Adenovirus polynucleotides and polypeptides
PCT/EP2016/063329 WO2016198621A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides

Publications (1)

Publication Number Publication Date
MX2017016101A true MX2017016101A (es) 2018-02-21

Family

ID=57503533

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016101A MX2017016101A (es) 2015-06-12 2016-06-10 Polinucleotidos y polipetidos de adenovirus.
MX2017016105A MX2017016105A (es) 2015-06-12 2016-06-10 Polinucleotidos y polipeptidos de adenovirus.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017016105A MX2017016105A (es) 2015-06-12 2016-06-10 Polinucleotidos y polipeptidos de adenovirus.

Country Status (13)

Country Link
US (4) US11254711B2 (enExample)
EP (2) EP3307313A1 (enExample)
JP (2) JP6983665B2 (enExample)
KR (2) KR102535670B1 (enExample)
CN (2) CN108025058B (enExample)
AU (4) AU2016275619B2 (enExample)
BE (1) BE1024420B1 (enExample)
BR (1) BR112017026523A2 (enExample)
CA (2) CA2988654A1 (enExample)
EA (1) EA038402B9 (enExample)
IL (2) IL256069B2 (enExample)
MX (2) MX2017016101A (enExample)
WO (2) WO2016198621A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038402B9 (ru) 2015-06-12 2021-09-22 Глаксосмитклайн Байолоджикалс Са Аденовирусные полинуклеотиды и полипептиды
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
ES2959811T3 (es) * 2016-12-09 2024-02-28 Glaxosmithkline Biologicals Sa Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
WO2019076892A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ENHANCED PROMOTER
CN111479926A (zh) 2017-10-16 2020-07-31 葛兰素史密丝克莱恩生物有限公司 具有两个表达盒的猿猴腺病毒载体
SG11202003058UA (en) 2017-10-16 2020-04-29 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
US11859199B2 (en) 2017-10-16 2024-01-02 Glaxosmithkline Biologicals Sa Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof
MX2020004487A (es) * 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus y usos de estos.
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
BR112020012361A2 (pt) 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
CN112638936A (zh) * 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
US20210277417A1 (en) * 2018-06-25 2021-09-09 Akouos, Inc. Methods of treating clrn1-associated hearing loss and/or vision loss
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
EP3810277A1 (en) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
EP3897846A1 (en) 2018-12-21 2021-10-27 GlaxoSmithKline Biologicals SA Methods of inducing an immune response
US20220339281A1 (en) 2019-03-05 2022-10-27 GalxoSmithKline Biologicals SA Hepatitis b immunisation regimen and compositions
US20230109362A1 (en) 2020-05-14 2023-04-06 Glaxosmithkline Biologicals Sa Viral biosensors
WO2025038011A1 (en) * 2023-08-11 2025-02-20 Joint Stock Company «Biocad» Modified sequence of adenovirus e2a gene for producing vectors based on adeno-associated viruses (aav) (variants)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
ES2322043T3 (es) 2001-06-22 2009-06-16 The Wistar Institute Of Anatomy And Biology Procedimientos de indusccion de una respuesta citotoxica inmune y composiciones de adenovirus de simio recombinante utiles en los mismos.
KR100987360B1 (ko) * 2001-11-21 2010-10-12 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 원숭이 아데노바이러스 핵산과 아미노산 서열, 이를함유하는 벡터 및 사용방법
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7205342B2 (en) * 2003-10-10 2007-04-17 General Electric Company Poly(arylene ether) composition and method of molding
ES2871907T3 (es) 2004-01-23 2021-11-02 Msd Italia Srl Portadores de vacuna de adenovirus de chimpancé
EP2848692B1 (en) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus vectors for influenza virus vaccines
NZ555907A (en) * 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
CA2608316A1 (en) * 2005-05-12 2006-11-16 Glaxo Group Limited Vaccine composition
EP1893636A2 (en) * 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
HUE031411T2 (en) 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
CA2706257C (en) * 2007-11-28 2017-06-06 The Trustees Of The University Of Pennsylvania Simian subfamily b adenovirus sadv-28, -27, -29, -32, -33 and -35 and uses thereof
EP2220217A2 (en) 2007-11-28 2010-08-25 The Trustees of the University of Pennsylvania Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof
CN101883858B (zh) * 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
CN102016011B (zh) * 2008-03-04 2013-12-11 宾夕法尼亚大学托管会 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
MX2011007980A (es) 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
CA2762203A1 (en) * 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
US8865182B2 (en) * 2009-07-31 2014-10-21 Paxvax, Inc. Adenoviral-based vectors
WO2011130627A2 (en) * 2010-04-16 2011-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Chimpanzee adenoviral vector-based filovirus vaccines
US20110293700A1 (en) 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US20120321694A1 (en) 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
FR2978457A1 (fr) * 2011-07-27 2013-02-01 Univ Paris Diderot Paris 7 Composes contenant un vecteur viral a specificite hepatique et presentant une activite anti-inflammatoire
IN2014DN03005A (enExample) 2011-10-05 2015-05-08 Genvec Inc
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
AP2014007993A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against RSV
WO2014019718A1 (en) 2012-08-01 2014-02-06 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
BR112015011389A2 (pt) * 2012-11-20 2017-08-22 Glaxosmithkline Biologicals Sa Complexo f do vírus sincicial respiratório, métodos para produzir um complexo f do vírus sincicial respiratório e para indução de uma resposta imunológica a um f de rsv em um indivíduo, e, composição imunogênica
DE102012221236A1 (de) 2012-11-21 2014-05-22 Zf Friedrichshafen Ag Getriebe
GB201303406D0 (en) * 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition
KR102039520B1 (ko) 2013-04-18 2019-11-01 이뮨 디자인 코포레이션 암 치료에 이용하기 위한 gla 단일요법
CN103937835A (zh) * 2013-08-19 2014-07-23 中国科学院上海巴斯德研究所 一种基于腺病毒AdC68的表达载体及其构建方法
CN103923943B (zh) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 一种基于腺病毒AdC7的表达载体及其构建方法
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
CN106659777A (zh) 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 免疫原性组合产品
EA038402B9 (ru) 2015-06-12 2021-09-22 Глаксосмитклайн Байолоджикалс Са Аденовирусные полинуклеотиды и полипептиды

Also Published As

Publication number Publication date
EP3307314A1 (en) 2018-04-18
CN107921118B (zh) 2022-11-08
CA2988654A1 (en) 2016-12-15
WO2016198599A1 (en) 2016-12-15
KR20180012857A (ko) 2018-02-06
JP6873054B2 (ja) 2021-05-19
EP3307313A1 (en) 2018-04-18
AU2019271972B2 (en) 2022-03-31
US20180170972A1 (en) 2018-06-21
IL256069A (en) 2018-01-31
CN107921118A (zh) 2018-04-17
BE1024420A1 (fr) 2018-02-12
BR112017026523A2 (pt) 2018-08-14
JP6983665B2 (ja) 2021-12-17
AU2019202081A1 (en) 2019-04-18
US20220204566A1 (en) 2022-06-30
IL256121B2 (en) 2023-02-01
JP2018524977A (ja) 2018-09-06
IL256121B (en) 2022-10-01
MX2017016105A (es) 2018-05-15
US20200140886A1 (en) 2020-05-07
WO2016198621A1 (en) 2016-12-15
KR102535670B1 (ko) 2023-05-22
IL256069B2 (en) 2023-07-01
IL256121A (en) 2018-02-28
AU2019202081B2 (en) 2021-09-23
AU2016275601A1 (en) 2018-01-18
BE1024420B1 (fr) 2018-02-19
IL256069B1 (en) 2023-03-01
EA201792651A1 (ru) 2018-06-29
US20220220157A1 (en) 2022-07-14
EA038402B9 (ru) 2021-09-22
CA2988481A1 (en) 2016-12-15
CN108025058B (zh) 2022-12-16
CN108025058A (zh) 2018-05-11
US11254711B2 (en) 2022-02-22
JP2018523980A (ja) 2018-08-30
KR20180011265A (ko) 2018-01-31
US11254710B2 (en) 2022-02-22
EA038402B1 (ru) 2021-08-23
AU2016275619A1 (en) 2018-01-04
AU2016275619B2 (en) 2019-09-19
AU2019271972A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
MX2017016105A (es) Polinucleotidos y polipeptidos de adenovirus.
MX2019006725A (es) Polinucleotidos y polipeptidos de adenovirus.
EA201791426A1 (ru) Полипептид и иммуномодуляция
PH12018501355A1 (en) Rsv f protein mutants
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
NZ731571A (en) T cell receptors
MX389173B (es) Receptores de celulas t.
ZA202302340B (en) Compositions and methods for treating celiac sprue disease
UY36565A (es) Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, asi como procedimientos para la division de toxinas de fusarium
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
EP3760713A3 (en) Lipase variants and polynucleotides encoding same
BR112017020308A2 (pt) udp-glicosiltransferases
EP4059961A3 (en) Anti-tau constructs
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
WO2015107363A3 (en) Mycobacterial antigen composition
MX2020013553A (es) Polinucleotidos y polipeptidos de adenovirus.
MX2021014856A (es) Vacuna de tgf-beta.
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение
PH12017502323B1 (en) Novel xylanase
AR101146A1 (es) Proteína con actividad xilanasa
MX2018003162A (es) Variante en el numero de copias que genera resistencia a virus.
WO2016036635A8 (en) Chromobacterium subtsugae genes
AU2019350356A8 (en) Arginase1 polypeptides
CA2909744C (en) Protransduzin b, an enhancer of gene transfer
PH12019501164A1 (en) Trehalose phosphorylase